Geron Corp. (GERN)
1.12
-0.01
(-0.88%)
USD |
NASDAQ |
Oct 23, 16:00
1.115
0.00 (0.00%)
After-Hours: 20:00
Geron Enterprise Value : 668.60M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 668.60M |
| October 22, 2026 | 675.02M |
| October 21, 2026 | 694.30M |
| October 20, 2026 | 745.69M |
| October 19, 2026 | 720.00M |
| October 16, 2026 | 700.72M |
| October 15, 2026 | 739.27M |
| October 14, 2026 | 713.57M |
| October 13, 2026 | 720.00M |
| October 12, 2026 | 732.85M |
| October 09, 2026 | 736.06M |
| October 08, 2026 | 732.85M |
| October 07, 2026 | 720.00M |
| October 06, 2026 | 726.42M |
| October 05, 2026 | 726.42M |
| October 02, 2026 | 720.00M |
| October 01, 2026 | 726.42M |
| September 30, 2026 | 739.27M |
| September 29, 2026 | 745.69M |
| September 28, 2026 | 752.12M |
| September 25, 2026 | 758.54M |
| September 24, 2026 | 758.54M |
| September 23, 2026 | 745.69M |
| September 22, 2026 | 790.67M |
| September 21, 2026 | 784.24M |
| Date | Value |
|---|---|
| September 18, 2026 | 784.24M |
| September 17, 2026 | 797.09M |
| September 16, 2026 | 777.82M |
| September 15, 2026 | 790.67M |
| September 14, 2026 | 829.22M |
| September 11, 2026 | 816.37M |
| September 10, 2026 | 829.22M |
| September 09, 2026 | 848.49M |
| September 08, 2026 | 919.16M |
| September 04, 2026 | 957.71M |
| September 03, 2026 | 919.16M |
| September 02, 2026 | 970.56M |
| September 01, 2026 | 899.89M |
| August 31, 2026 | 906.31M |
| August 28, 2026 | 919.16M |
| August 27, 2026 | 932.01M |
| August 26, 2026 | 932.01M |
| August 25, 2026 | 944.86M |
| August 24, 2026 | 925.59M |
| August 21, 2026 | 925.59M |
| August 20, 2026 | 944.86M |
| August 19, 2026 | 970.56M |
| August 18, 2026 | 932.01M |
| August 17, 2026 | 932.01M |
| August 14, 2026 | 893.46M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Precigen, Inc. | 2.276B |
| Editas Medicine, Inc. | 228.08M |
| Agenus, Inc. | 534.42M |
| Amgen, Inc. | 280.78B |
| Anika Therapeutics, Inc. | 273.50M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.68M |
| Revenue (Quarterly) | 57.48M |
| Total Expenses (Quarterly) | 74.16M |
| EPS Diluted (Quarterly) | -0.0249 |
| Gross Profit Margin (Quarterly) | 94.94% |
| Profit Margin (Quarterly) | -29.02% |
| Earnings Yield | -9.34% |
| Normalized Earnings Yield | -7.795 |